<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Immunoprecise Antibodies Ltd — News on 6ix</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd</link>
<description>Latest news and press releases for Immunoprecise Antibodies Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 13 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/immunoprecise-antibodies-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835847378dffbe2df0fd1c1.webp</url>
<title>Immunoprecise Antibodies Ltd</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd</link>
</image>
<item>
<title>PPL Electric Utilities reaches settlement in first distribution rate increase since 2016</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/ppl-electric-utilities-reaches-settlement-in-first-distribution-rate-increase-since-2016-327</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/ppl-electric-utilities-reaches-settlement-in-first-distribution-rate-increase-since-2016-327</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>If approved by the PUC, increase would support continued enhancements in reliability and further support vulnerable customers.ALLENTOWN, Pa., March 13, 2026</description>
</item>
<item>
<title>NewtekOne, Inc. Declares Dividends on Common Stock and Series B Preferred Shares</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/newtekone-inc-declares-dividends-on-common-stock-and-series-b-preferred-shares-442</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/newtekone-inc-declares-dividends-on-common-stock-and-series-b-preferred-shares-442</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., March 13, 2026 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (“the Company”) (NASDAQ: NEWT) announced that its Board of Directors declared a quarterly</description>
</item>
<item>
<title>Transaction in Own Shares</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/transaction-in-own-shares-441</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/transaction-in-own-shares-441</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Transaction in Own Shares 13 March 2026 • • • • • • • • • • • • • • • • Shell plc (the ‘Company’) announces that on 13 March 2026 it purchased the following</description>
</item>
<item>
<title>RLJ Lodging Trust Announces Dividends for First Quarter of 2026</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/rlj-lodging-trust-announces-dividends-for-first-quarter-of-2026-423</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/rlj-lodging-trust-announces-dividends-for-first-quarter-of-2026-423</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>BETHESDA, Md.--(BUSINESS WIRE)-- RLJ Lodging Trust (the “Company”) (NYSE: RLJ) today announced that its Board of Trustees has declared a quarterly cash</description>
</item>
<item>
<title>Nexentis Technologies Inc. Launches New Corporate Website, Showcasing Innovative AI-Driven Biotech Platform</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/nexentis-technologies-inc-launches-new-corporate-website-showcasing-innovative-ai-driven-biotech-platform-346</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/nexentis-technologies-inc-launches-new-corporate-website-showcasing-innovative-ai-driven-biotech-platform-346</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Visit Nexentis at: www.nexentistech.com Neve Yarak, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), (“Nexentis” and the</description>
</item>
<item>
<title>Green Rain Energy (OTCID: GREH) Announces Review of Legacy Convertible Notes and Strengthened Shareholder Protections</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/green-rain-energy-otcid-greh-announces-review-of-legacy-convertible-notes-and-strengthened-shareholder-protections-326</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/green-rain-energy-otcid-greh-announces-review-of-legacy-convertible-notes-and-strengthened-shareholder-protections-326</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>BEVERLY HILLS, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- (“Green Rain Energy” or the “Company”) today announced that, following recently filed Form 8-K</description>
</item>
<item>
<title>Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/biophytis-lynxkite-alliance-expands-to-turbocharge-ai-driven-drug-discovery-for-next-generation-longevity-therapeutics-226</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/biophytis-lynxkite-alliance-expands-to-turbocharge-ai-driven-drug-discovery-for-next-generation-longevity-therapeutics-226</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapiesThis partnership will generate</description>
</item>
<item>
<title>Eastman CFO Willie McLain to Address J.P. Morgan Industrials Conference</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/eastman-cfo-willie-mclain-to-address-jp-morgan-industrials-conference-385</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/eastman-cfo-willie-mclain-to-address-jp-morgan-industrials-conference-385</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>KINGSPORT, Tenn.--(BUSINESS WIRE)-- Industrials Conference Willie McLain, Executive Vice President and Chief Financial Officer, Eastman Chemical Company</description>
</item>
<item>
<title>Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/akari-therapeutics-releases-ceo-corner-highlighting-strategic-progress-and-path-to-clinical-development-under-ceo-abizer-gaslightwala-421</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/akari-therapeutics-releases-ceo-corner-highlighting-strategic-progress-and-path-to-clinical-development-under-ceo-abizer-gaslightwala-421</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and expansion of Akari’s ADC pipeline Access</description>
</item>
<item>
<title>Nutanix Announces Investor Day 2026 Details</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/nutanix-announces-investor-day-2026-details-364</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/nutanix-announces-investor-day-2026-details-364</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN JOSE, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Nutanix, Inc. (NASDAQ: NTNX), a leader in hybrid multicloud computing, will host its Investor Day 2026 on</description>
</item>
<item>
<title>Heartland Express, Inc. Declares Regular Quarterly Dividend</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/heartland-express-inc-declares-regular-quarterly-dividend-440</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/heartland-express-inc-declares-regular-quarterly-dividend-440</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>NORTH LIBERTY, Iowa, March 13, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Heartland Express, Inc. (Nasdaq: HTLD) announced today the declaration of a</description>
</item>
<item>
<title>Recon Technology, Ltd Reports Financial Results for the First Six Months of Fiscal Year 2026</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/recon-technology-ltd-reports-financial-results-for-the-first-six-months-of-fiscal-year-2026-430</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/recon-technology-ltd-reports-financial-results-for-the-first-six-months-of-fiscal-year-2026-430</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>BEIJING, March 13, 2026 /PRNewswire/ -- Recon Technology, Ltd (NASDAQ: RCON) ("Recon" or the "Company"), a China-based independent solutions integrator in the</description>
</item>
<item>
<title>Sigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale Initiatives</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/sigyn-therapeutics-issues-shareholder-update-regarding-potential-merger-and-asset-sale-initiatives-394</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/sigyn-therapeutics-issues-shareholder-update-regarding-potential-merger-and-asset-sale-initiatives-394</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, CA - March 13, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), a developer of dialysis-like therapies to</description>
</item>
<item>
<title>Travelers Schedules Conference Call to Review First Quarter 2026 Results</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/travelers-schedules-conference-call-to-review-first-quarter-2026-results-427</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/travelers-schedules-conference-call-to-review-first-quarter-2026-results-427</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- The Travelers Companies, Inc. (NYSE: TRV) will review its first quarter 2026 results at 9:30 a.m. ET on Thursday, April 16,</description>
</item>
<item>
<title>American Vanguard Announces Date of Full Year 2025 Earnings Release and Webcast Conference Call</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/american-vanguard-announces-date-of-full-year-2025-earnings-release-and-webcast-conference-call-288</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/american-vanguard-announces-date-of-full-year-2025-earnings-release-and-webcast-conference-call-288</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>NEWPORT BEACH, CA / ACCESS Newswire / March 13, 2026 / American Vanguard® Company announced today that it will report financial results for the full year</description>
</item>
<item>
<title>Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/alpha-cognition-nasdaq-acog-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-thursday-march-26-2026-340</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/alpha-cognition-nasdaq-acog-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-thursday-march-26-2026-340</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Management to host conference call on Thursday, March 26, 2026 at 4:30pm ET VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc.</description>
</item>
<item>
<title>Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/tevogenai-reports-advancements-in-predictcelltm-beta-demonstrates-improved-precision-metrics-and-expands-proprietary-ai-infrastructure-336</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/tevogenai-reports-advancements-in-predictcelltm-beta-demonstrates-improved-precision-metrics-and-expands-proprietary-ai-infrastructure-336</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements</description>
</item>
<item>
<title>Innovation Beverage Group Limited Announces Pricing of $6 Million Public Offering</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/innovation-beverage-group-limited-announces-pricing-of-dollar6-million-public-offering-401</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/innovation-beverage-group-limited-announces-pricing-of-dollar6-million-public-offering-401</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>SYDNEY, March 13, 2026 (GLOBE NEWSWIRE) -- Innovation Beverage Group Limited (NASDAQ: IBG) (the “Company”), an innovative developer, manufacturer, and</description>
</item>
<item>
<title>Orbit International Reports Consolidated Bookings for Month of February 2026 in Excess of $2,100,000</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/orbit-international-reports-consolidated-bookings-for-month-of-february-2026-in-excess-of-dollar2100000-1</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/orbit-international-reports-consolidated-bookings-for-month-of-february-2026-in-excess-of-dollar2100000-1</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>FIRM BOOKINGS OF APPROXIMATELY $1,000,000 FOR FEBRUARY 2026 FROM SIMULATOR PRODUCT SOLUTIONS LLC SUBSIDIARY ALSO FIRM BOOKINGS FROM ORBIT POWER GROUP ON</description>
</item>
<item>
<title>Splash Beverage Group Signs Letter of Intent for Acquisition and Merger With Established Hemp and CBD Operator Medterra</title>
<link>https://6ix.com/company/immunoprecise-antibodies-ltd/news/splash-beverage-group-signs-letter-of-intent-for-acquisition-and-merger-with-established-hemp-and-cbd-operator-medterra-1</link>
<guid isPermaLink="true">https://6ix.com/company/immunoprecise-antibodies-ltd/news/splash-beverage-group-signs-letter-of-intent-for-acquisition-and-merger-with-established-hemp-and-cbd-operator-medterra-1</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Proposed Combination Marks Strategic Re-Alignment as a Public Cannabinoid Wellness Platform FORT LAUDERDALE, FL - March 5, 2026 (NEWMEDIAWIRE) - Splash</description>
</item>
</channel>
</rss>